JGC
ALT icon

J. Goldman & Co’s Altimmune ALT Stock Holding History

J. Goldman & Co’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-55,935
Closed -$714K – 367
2022
Q3 		$714K Buy
+55,935
New +$826K 0.03% 275
2015
Q1 		– Sell
-543
Closed -$295K – 264
2014
Q4 		$295K Hold
543
– – 0.03% 168
2014
Q3 		$290K Buy
543
+211
+64% +$110K 0.02% 261
2014
Q2 		$140K Buy
332
+88
+36% +$39.8K 0.01% 228
2014
Q1 		$134K Sell
244
-48
-16% -$28K 0.01% 236
2013
Q4 		$163K Buy
292
+48
+20% +$28.6K 0.02% 202
2013
Q3 		$154K Buy
+244
New +$140K 0.01% 246

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

J. Goldman & Co's ALT Position: Q4 2022 in Review

J. Goldman & Co sold out of Altimmune (ALT) in Q4 2022, closing a stake of 55,935 shares — an estimated $714K sold.

J. Goldman & Co first reported a position in ALT in Q3 2013 and held it in 7 quarters. The position peaked at $714K in Q3 2022. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • J. Goldman & Co reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • J. Goldman & Co sold 55,935 Altimmune shares in Q4 2022, an estimated $714K.
  • J. Goldman & Co first reported a position in Altimmune in Q3 2013 and held it in 7 quarters.
  • J. Goldman & Co's Altimmune position peaked at $714K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.